Last reviewed · How we verify
FSC
FSC is a combination therapy that works through dual mechanisms to treat respiratory and inflammatory conditions.
FSC is a combination therapy that works through dual mechanisms to treat respiratory and inflammatory conditions. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | FSC |
|---|---|
| Also known as | Advair (tm) |
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor; Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
FSC typically refers to a fixed-dose combination of fluticasone propionate (a corticosteroid) and salmeterol (a long-acting beta-2 agonist), commonly known by the brand name Seretide/Advair. The fluticasone reduces airway inflammation while salmeterol provides bronchodilation through beta-2 receptor agonism. This combination addresses both the inflammatory and obstructive components of chronic respiratory disease.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
Key clinical trials
- An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older (PHASE2)
- Tele-rehabilitation Program: An Innovative and Sustainable Early Intervention Service for Children With Autism Spectrum Disorders (NA)
- An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) (PHASE3)
- Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies
- NATURE 3.1_New Approach for the Reduction of REnal Uremic Toxins (NA)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- Somerset and South Essex Coronavirus Antigen Testing (NA)
- NATURE 3.2_New Approach for the Reduction of REnal Uremic Toxins (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |